Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin + betamethasone valerate is a combination of two pharmaceutical agents, each with distinct mechanisms and therapeutic roles. Atorvastatin is an oral statin (HMG-CoA reductase inhibitor) primarily used to lower cholesterol and triglyceride levels, thereby reducing the risk of cardiovascular events such as heart attack and stroke. It also exhibits anti-inflammatory and immunomodulatory effects that may benefit inflammatory skin conditions[5][6][7]. Betamethasone valerate is a synthetic corticosteroid applied topically to reduce inflammation, itching, and redness in various dermatological conditions by suppressing local immune responses[3]. The combination has been investigated for enhanced efficacy in treating chronic inflammatory skin diseases such as psoriasis and hand eczema, leveraging both the lipid-lowering/anti-inflammatory properties of atorvastatin and the potent topical anti-inflammatory action of betamethasone valerate[6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + betamethasone valerate.